These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 28650866)

  • 1. Obesity and metabolic stone disease.
    Wollin DA; Skolarikos A; Preminger GM
    Curr Opin Urol; 2017 Sep; 27(5):422-427. PubMed ID: 28650866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity and stones.
    Sarica K
    Curr Opin Urol; 2019 Jan; 29(1):27-32. PubMed ID: 30308572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of being overweight on urinary metabolic risk factors for kidney stone formation.
    Shavit L; Ferraro PM; Johri N; Robertson W; Walsh SB; Moochhala S; Unwin R
    Nephrol Dial Transplant; 2015 Apr; 30(4):607-13. PubMed ID: 25362001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic Syndrome and Kidney Stone Disease: A Systematic Review of Literature.
    Wong Y; Cook P; Roderick P; Somani BK
    J Endourol; 2016 Mar; 30(3):246-53. PubMed ID: 26576717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The new patterns of nephrolithiasis: What has been changing in the last millennium?
    Cicerello E; Ciaccia M; Cova GD; Mangano MS
    Arch Ital Urol Androl; 2021 Jun; 93(2):195-199. PubMed ID: 34286555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity and kidney stone disease: a systematic review.
    Carbone A; Al Salhi Y; Tasca A; Palleschi G; Fuschi A; De Nunzio C; Bozzini G; Mazzaferro S; Pastore AL
    Minerva Urol Nefrol; 2018 Aug; 70(4):393-400. PubMed ID: 29856171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association of cardiovascular disease and metabolic syndrome with nephrolithiasis.
    Lange JN; Mufarrij PW; Wood KD; Holmes RP; Assimos DG
    Curr Opin Urol; 2012 Mar; 22(2):154-9. PubMed ID: 22262248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients.
    Ekeruo WO; Tan YH; Young MD; Dahm P; Maloney ME; Mathias BJ; Albala DM; Preminger GM
    J Urol; 2004 Jul; 172(1):159-63. PubMed ID: 15201761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obesity and urolithiasis: evidence of regional influences.
    Trinchieri A; Croppi E; Montanari E
    Urolithiasis; 2017 Jun; 45(3):271-278. PubMed ID: 27488444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic syndrome and stone disease.
    Soligo M; Morlacco A; Zattoni F; Valotto C; DE Giorgi G; Beltrami P
    Panminerva Med; 2022 Sep; 64(3):344-358. PubMed ID: 34609121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic syndrome and nephrolithiasis: a systematic review and meta-analysis of the scientific evidence.
    Rendina D; De Filippo G; D'Elia L; Strazzullo P
    J Nephrol; 2014 Aug; 27(4):371-6. PubMed ID: 24696310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is oxidative stress, a link between nephrolithiasis and obesity, hypertension, diabetes, chronic kidney disease, metabolic syndrome?
    Khan SR
    Urol Res; 2012 Apr; 40(2):95-112. PubMed ID: 22213019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrolithiasis in the Obese Patient.
    Kelly C; Geraghty RM; Somani BK
    Curr Urol Rep; 2019 May; 20(7):36. PubMed ID: 31104149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
    Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
    Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kidney stones diseases and glycaemic statuses: focus on the latest clinical evidences.
    Spatola L; Angelini C; Badalamenti S; Maringhini S; Gambaro G
    Urolithiasis; 2017 Oct; 45(5):457-460. PubMed ID: 27921141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrolithiasis in Israel: Epidemiological Characteristics of Return Patients in a Tertiary Care Center.
    Abu-Ghanem Y; Kleinmann N; Winkler HZ; Zilberman DE
    Isr Med Assoc J; 2016 Dec; 18(12):725-728. PubMed ID: 28457074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal stone disease and obesity: what is important for urologists and nephrologists?
    Ahmed MH; Ahmed HT; Khalil AA
    Ren Fail; 2012; 34(10):1348-54. PubMed ID: 23013150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management.
    Sakhaee K; Maalouf NM; Sinnott B
    J Clin Endocrinol Metab; 2012 Jun; 97(6):1847-60. PubMed ID: 22466339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between metabolic syndrome components and the risk of developing nephrolithiasis: A systematic review and bayesian meta-analysis.
    Rahman IA; Nusaly IF; Syahrir S; Nusaly H; Mansyur MA
    F1000Res; 2021; 10():104. PubMed ID: 34804491
    [No Abstract]   [Full Text] [Related]  

  • 20. The association of nephrolithiasis with hypertension and obesity: a review.
    Obligado SH; Goldfarb DS
    Am J Hypertens; 2008 Mar; 21(3):257-64. PubMed ID: 18219300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.